Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, has entered into a development and license agreement with SunGen Pharma, LLC to develop and commercialize four generic pharmaceutical products. The companies will share responsibilities and development costs, and upon approval, the products will be jointly owned. SunGen shall have the exclusive right to market and sell two of the products using SunGen’s label and Elite ...